The STOP-APE trial is a multicentre, randomised controlled, open-label, pragmatic clinical trial that will determine if withholding anticoagulation for the treatment of isolated or incidental subsegmental pulmonary embolism (SSPE) is better than treating it with standard anticoagulation therapy.
There will be 50 trial sites across the UK and approximately 1466 patients will be recruited on to the trial. More information about the trial and the essential trial documents can be found on the trial website.
The STOP-APE team are still looking for new sites to participate, so if you are interested please contact the trial office via STOPAPE@trials.bham.ac.uk
For all of the latest STOP-APE updates please follow the team on Twitter (@StopapeTrial)